European Journal of Internal Medicine
Volume 20, Issue 8 , Pages 749-755 , December 2009

Peptidylarginine deiminases and the pathogenesis of rheumatoid arthritis: A reflection of the involvement of transglutaminase in coeliac disease

  • Pål Stenberg

      Affiliations

    • Lund University, Department of Clinical Sciences, Malmö, Clinical Coagulation Research Unit, Malmö University Hospital, S-205 02 Malmö, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 40 26 52 94; fax: +46 40 33 62 55.
    • ,
  • Bodil Roth

      Affiliations

    • Lund University, Department of Clinical Sciences, Malmö, Clinical Coagulation Research Unit, Malmö University Hospital, S-205 02 Malmö, Sweden
    • ,
  • Frank A. Wollheim

      Affiliations

    • Department of Rheumatology, Lund University Hospital, S-221 85 Lund, Sweden

Received 26 June 2009 ,Revised 17 August 2009 ,Accepted 20 August 2009.

References 

  1. Doyle HA, Mamula MJ. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol. 2001;22(8):443–449
  2. Doyle HA, Mamula MJ. Posttranslational modifications of self-antigens. Ann N Y Acad Sci. 2005;1050:1–9
  3. Fox PC. Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci. 2007;1098:15–21
  4. Committee, T.A.D.C., Progress in autoimmune disease research: a report to congress. U.S. Department of Health and Human Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases. (Access at www.niaid.nih.gov/publications/pdf/ADCCFinal.pdf). 2005.
  5. Milioti N, Bermudez-Fajardo A, Penichet ML, Oviedo-Orta E. Antigen-induced immunomodulation in the pathogenesis of atherosclerosis.. Clin Dev Immunol. 2008;2008:723539
  6. Jellinger KA, Janetzky B, Attems J, Kienzl E. Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'–a new blood biomarker?. J Cell Mol Med. 2008;12(4):1094–1117
  7. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3(7):797–801
  8. Lorand L. Factor XIII and the clotting of fibrinogen: from basic research to medicine. J Thromb Haemost. 2005;3(7):1337–1348
  9. Dieterich W, Esslinger B, Schuppan D. Pathomechanisms in celiac disease. Int Arch Allergy Immunol. 2003;132(2):98–108
  10. Stenberg P, Roth EB, Sjoberg K. Transglutaminase and the pathogenesis of coeliac disease. Eur J Intern Med. 2008;19(2):83–91
  11. Gyorgy B, Toth E, Tarcsa E, Falus A, Buzas EI. Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol. 2006;38(10):1662–1677
  12. Tarcsa E, Marekov LN, Mei G, Melino G, Lee SC, Steinert PM. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem. 1996;271(48):30709–30716
  13. Tarcsa E, Marekov LN, Andreoli J, Idler WW, Candi E, Chung SI, et al. The fate of trichohyalin. Sequential post-translational modifications by peptidyl-arginine deiminase and transglutaminases. J Biol Chem. 1997;272(44):27893–27901
  14. Harauz G, Musse AA. A tale of two citrullines—structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem Res. 2007;32(2):137–158
  15. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays. 2003;25(11):1106–1118
  16. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol. 1999;162(1):585–594
  17. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci. 2008;1143:268–285
  18. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis. 2009;68(5):736–743
  19. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741–2749
  20. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46
  21. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther. 2005;7(3):R458–R467
  22. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstrom A, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med. 2009;206(2):449–462
  23. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol. 2003;171(2):538–541
  24. Harris ML, Darrah E, Lam GK, Bartlett SJ, Giles JT, Grant AV, et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum. 2008;58(7):1958–1967
  25. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 2004;50(7):2113–2121
  26. Kang CP, Lee HS, Ju H, Cho H, Kang C, Bae SC. A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis Rheum. 2006;54(1):90–96
  27. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 2003;34(4):395–402
  28. Burr ML, Naseem H, Hinks A, Eyre S, Gibbons L, Bowes J, et al. PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian Population. Ann Rheum Dis. 2009;
  29. Poor G, Nagy ZB, Schmidt Z, Brozik M, Meretey K, Gergely P. Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis. Ann N Y Acad Sci. 2007;1110:23–32
  30. Iwamoto T, Ikari K, Nakamura T, Kuwahara M, Toyama Y, Tomatsu T, et al. Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford). 2006;45(7):804–807
  31. Mechi MC, Sebbag M, Arnaud J, Nachat R, Foulquier C, Adoue V, et al. Update on peptidylarginine deiminases and deimination in skin physiology and severe human diseases. Int J Cosmet Sci. 2007;29(3):147–168
  32. Kearney PL, Bhatia M, Jones NG, Yuan L, Glascock MC, Catchings KL, et al. Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry. 2005;44(31):10570–10582
  33. Takizawa Y, Sawada T, Suzuki A, Yamada R, Inoue T, Yamamoto K. Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand J Rheumatol. 2005;34(3):212–215
  34. Roth B. Transglutaminase and peptidylarginine deiminase in the pathogenesis of autoimmune diseases. Doctorial Thesis: Lund University; 2008;
  35. Roth EB, Stenberg P, Book C, Sjoberg K. Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis–new pathways to epitope spreading. Clin Exp Rheumatol. 2006;24(1):12–18
  36. Zhao J, Zhao Y, He J, Jia R, Li Z. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol. 2008;35(6):969–974
  37. Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewe R, Odegard S, et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis. 2008;67(3):414–417
  38. Nissinen R, Paimela L, Julkunen H, Tienari PJ, Leirisalo-Repo M, Palosuo T, et al. Peptidylarginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren syndrome. Scand J Rheumatol. 2003;32(6):337–342
  39. Roth EB, Sjoberg K, Stenberg P. Biochemical and immuno-pathological aspects of tissue transglutaminase in coeliac disease. Autoimmunity. 2003;36(4):221–226
  40. Agardh D, Roth B, Lernmark A, Stenberg P. Calcium activation of tissue transglutaminase in radioligand binding and enzyme-linked autoantibody immunoassays in childhood celiac disease. Clin Chim Acta. 2005;358(1-2):95–103
  41. Roth EB, Theander E, Londos E, Sandberg-Wollheim M, Larsson Å, Sjöberg K, et al. Pathogenesis of Autoimmune Diseases: Antibodies Against Transglutaminase, Peptidylarginine Deiminase and Protein-bound Citrulline in Primary Sjogren"s Syndrome, Multiple Sclerosis and Alzheimer"s Disease. Scand J Immunol. 2008;67(6):626–631
  42. Riente L, Chimenti D, Pratesi F, Delle Sedie A, Tommasi S, Tommasi C, et al. Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol. 2004;31(5):920–924
  43. Picarelli A, Di Tola M, Sabbatella L, Vetrano S, Anania MC, Spadaro A, et al. Anti-tissue transglutaminase antibodies in arthritic patients: a disease-specific finding?. Clin Chem. 2003;49(12):2091–2094
  44. Di Tola M, Barilla F, Trappolini M, Palumbo HF, Gaudio C, Picarelli A. Antitissue transglutaminase antibodies in acute coronary syndrome: an alert signal of myocardial tissue lesion?. J Intern Med. 2008;263(1):43–51
  45. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(Suppl 3):S265–S272
  46. Senshu T, Akiyama K, Nagata S, Watanabe K, Hikichi K. Peptidylarginine deiminase in rat pituitary: sex difference, estrous cycle-related changes, and estrogen dependence. Endocrinology. 1989;124(6):2666–2670
  47. Gerosa M, De Angelis V, Riboldi P, Meroni PL. Rheumatoid arthritis: a female challenge. Womens Health (Lond Engl). 2008;4(2):195–201
  48. Seiving B, Ohlsson K, Linder , Stenberg P. Transglutaminase differentiation during maturation of human blood monocytes to macrophages. Eur J Haematol. 1991;46(5):263–271
  49. Wollheim FA, Stenberg P, Marsal L. Characterisation of transglutaminases in plasma and synovial fluid from patients with arthritis. In: 15th International Congress of Rheumatology. 1981;Paris
  50. Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis. 2004;63(4):373–381
  51. Musse AA, Polverini E, Raijmakers R, Harauz G. Kinetics of human peptidylarginine deiminase 2 (hPAD2)–reduction of Ca2+ dependence by phospholipids and assessment of proposed inhibition by paclitaxel side chains. Biochem Cell Biol. 2008;86(5):437–447
  52. Credo RB, Stenberg P, Tong YS, Lorand L. Inhibition of fibrinoligase and transglutaminase by zinc ions. In: Fed. Proc. 1976;San Fransisco
  53. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar S, Gottlieb P, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007;104(43):17040–17045
  54. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications. 2005;19(4):238–246
  55. Mathews JD, Whittingham S, Hooper BM, Mackay IR, Stenhouse NS. Association of autoantibodies with smoking, cardiovascular morbidity, and death in the Busselton population. Lancet. 1973;2(7832):754–758
  56. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum. 1996;39(5):732–735
  57. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651–675
  58. Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67(10):1488–1492
  59. Roth WJ, Fleit HB, Chung SI, Janoff A. Characterization of two distinct transglutaminases of murine bone marrow-derived macrophages: effects of exposure of viable cells to cigarette smoke on enzyme activity. J Leukoc Biol. 1987;42(1):9–20
  60. Galanakis DK, Laurent P, Janoff A. Cigarette smoke contains anticoagulants against fibrin aggregation and factor XIIIa in plasma. Science. 1982;217(4560):642–645
  61. Bengtsson AA, Rylander L, Hagmar L, Nivede O, Sturfelt G. Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheumatology (Oxford). 2002;41(5):563–571
  62. Jonsson IM, Verdrengh M, Brisslert M, Lindblad S, Bokarewa M, Islander U, et al. Ethanol prevents development of destructive arthritis. Proc Natl Acad Sci U S A. 2007;104(1):258–263
  63. Kallberg H, Jacobsen S, Bengtsson C, Pedersen M, Padyukov L, Garred P, et al. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis. 2009;68(2):222–227
  64. Kim SK, Park SH, Shin IH, Choe JY. Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. J Rheumatol. 2008;35(6):995–1001
  65. Suchocki EA, Brecher AS. The effect of acetaldehyde on human plasma factor XIII function. Dig Dis Sci. 2007;52(12):3488–3492
  66. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045
  67. Kelly S, Dunham JP, Donaldson LF. Sensory nerves have altered function contralateral to a monoarthritis and may contribute to the symmetrical spread of inflammation. Eur J Neurosci. 2007;26(4):935–942
  68. Luo Y, Arita K, Bhatia M, Knuckley B, Lee YH, Stallcup MR, et al. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry. 2006;45(39):11727–11736
  69. Knuckley B, Luo Y, Thompson PR. Profiling protein arginine deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem. 2008;16(2):739–745
  70. Oak S, Gilliam LK, Landin-Olsson M, Torn C, Kockum I, Pennington CR, et al. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci U S A. 2008;105(14):5471–5476
  71. Ju JH, Cho ML, Jhun JY, Park MJ, Oh HJ, Min SY, et al. Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T cells in collagen-induced arthritis. Immunol Lett. 2008;117(1):16–25

PII: S0953-6205(09)00165-4

doi: 10.1016/j.ejim.2009.08.007

European Journal of Internal Medicine
Volume 20, Issue 8 , Pages 749-755 , December 2009

Article Tools

* Image Usage & Resolution